Wuhan Keqian Biology Co.,Ltd (SHA:688526)
China
· Delayed Price · Currency is CNY 16.00
+0.15 (0.95%)
Mar 10, 2026, 9:54 AM CST
SHA:688526 Revenue
In the year 2025, Wuhan Keqian Biology Co.,Ltd had annual revenue of 950.29M CNY with 0.89% growth. Wuhan Keqian Biology Co.,Ltd had revenue of 212.43M in the quarter ending December 31, 2025, a decrease of -23.15%.
Revenue
950.29M
Revenue Growth
+0.89%
P/S Ratio
7.74
Revenue / Employee
1.03M
Employees
922
Market Cap
7.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 950.29M | 8.37M | 0.89% |
| Dec 31, 2024 | 941.92M | -122.15M | -11.48% |
| Dec 31, 2023 | 1.06B | 62.81M | 6.27% |
| Dec 31, 2022 | 1.00B | -101.75M | -9.22% |
| Dec 31, 2021 | 1.10B | 259.79M | 30.81% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Acrobiosystems | 794.52M |
| Jiangsu Aidea Pharmaceutical Group | 720.67M |
| Zhejiang Ausun Pharmaceutical | 751.12M |
| Suzhou Fengbei Biotech Stock | 2.81B |
| Anhui Huaheng Biotechnology | 2.89B |
| Nanjing Vazyme Biotech | 1.38B |
| Chengdu Kanghua Biological Products | 1.21B |
| Jiangxi Fushine Pharmaceutical | 970.32M |